/
We are a biopharmaceutical company, enabled by a world-class generics business. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients needs, now and in the future.
12.50% operating margin is respectable but not wide. ROIC at 6.51%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 4.3%, steady but not accelerating.
Net debt of $15.52B represents 13.5x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
$17.35B
▲ +4.3% YoY
Net Income (TTM)
$1.56B
▲ +186.0% YoY
Op. Margin
13.20%
▲ +14.3pp YoY
ROIC
6.96%
▲ +7.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.17B
▲ +53.3% YoY
Op. Cash Flow (TTM)
$1.71B
▲ +32.2% YoY
Net Debt
$15.82B
Cash & Equiv.
$3.74B
3Y CAGR: +5.0%
3Y CAGR: +3.3%
Continue Research